珍寶島(603567.SH):鹽酸莫西沙星獲得化學原料藥上市申請批准通知書
格隆匯3月15日丨珍寶島(603567.SH)公佈,收到鹽酸莫西沙星的《化學原料藥上市申請批准通知書》,表明該原料藥已符合國家相關原料藥審評技術標準,在符合藥品生產質量管理規範要求後,可在國內市場進行生產銷售,將進一步豐富黑龍江珍寶島藥業股份有限公司的產品線,有助於拓寬公司的業務領域。鹽酸莫西沙星屬於第四代抗生素,主要應用於慢性支氣管炎的急性加劇患者,慢性阻塞性肺病,社區獲得性肺炎,急性細菌性鼻竇炎等。臨牀上常用於治療常規抗生素治療不佳,或者常規抗生素耐藥後的患者,具有廣譜、耐藥性低、半衰期長以及不良反應少等特點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.